TY  - JOUR
AU  - Popov, Mikhail Aleksandrovich 
AU  - Poznyak, Anastasia Vladimirovna 
AU  - Shumakov, Dmitry Valerievich 
AU  - Zybin, Dmitry Igorevich 
AU  - Kashirina, Natalia Mikhailovna 
AU  -  Lipatova, Liudmila Nikolaevna 
AU  - Peklo, Mikhail Mikhailovich 
AU  - Rutkevich, Pavel Nikolaevich 
AU  - Yanushevskaya, Elena Vadimovna 
AU  - Pleshko, Elizaveta Mikhailovna 
AU  - Glanz, Victor Yurievich 
AU  - Sukhorukov, Vasily Nikolaevich 
AU  - Beloyartsev, Dmitry Felixovich 
AU  - Orekhov, Alexander Nikolaevich 
PY  - 2024
TI  - MMP-9 is a Potential Prognostic Marker of Left Ventricular Remodeling in Patients with Coronary Artery Disease
JF  - OnLine Journal of Biological Sciences
VL  - 24
IS  - 4
DO  - 10.3844/ojbsci.2024.720.727
UR  - https://thescipub.com/abstract/ojbsci.2024.720.727
AB  - Matrix Metalloproteinase-9 (MMP-9) emerges as a promising prognostic marker for assessing left ventricular remodeling in patients with coronary artery disease, particularly in the context of Ischemic Heart Disease (IHD) complicated by left ventricular aneurysm. In this study, we conducted two parallel investigations to explore the prognostic significance of MMP-9 in patients with multivessel coronary artery disease undergoing left ventricular reconstruction via coronary artery bypass grafting. Two distinct cohorts were examined in this research. The first group underwent analysis of MMP-9 levels in biopsies of the left ventricular myocardium, focusing on paracollagen type 4-MMP-9. The second group had their blood plasma MMP-9 concentrations scrutinized. The study primarily aimed to assess the predictive value of MMP-9 in determining postoperative prognoses and treatment outcomes. Our initial findings from the biopsy analysis revealed a significant association (p = 0.001) between para-collagen type 4-MMP-9 levels and unfavorable prognoses in the early postoperative period. Furthermore, monitoring MMP-9 levels in blood plasma for 5 years indicated a correlation between elevated MMP-9 concentrations and ongoing ischemic changes post-myocardial revascularization, suggesting a progression toward congestive heart failure. Notably, a substantial decrease (p = 0.002) in MMP-9 concentration was observed in patients post-surgery, underscoring the positive impact of myocardial revascularization on MMP-9 levels. The research underscores the potential of MMP-9 as a valuable marker for predicting adverse outcomes post-myocardial revascularization and myocardial remodeling surgery. Elevated MMP-9 levels in plasma signify a risk of CHF progression, while decreased levels post-surgery point towards the benefits of revascularization interventions. This study offers critical insights into leveraging MMP-9 as a prognostic tool in guiding optimal treatment strategies for patients with coronary artery disease and left ventricular remodeling, emphasizing its relevance in enhancing patient care and clinical decision-making